R&D Tax Incentive of $570k Received to Support Development
Sydney, Dec 22, 2014 AEST (ABN Newswire) - Melbourne technology firm, Rhinomed (
ASX:RNO) is pleased to announce that it has received a Research and Development tax refund of $570,337.
Rhinomed Limited intends to apply these funds to continue the development and commercialization of its BreatheAssist platform technology and for working capital purposes.
About Rhinomed Limited
Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global
Follow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring
| ||
|
